TY - JOUR

T1 - Dexrazoxane for anthracycline extravasation

AU - Langer, Seppo W

PY - 2007/8

Y1 - 2007/8

N2 - Accidental extravasation of anthracycline-containing anticancer chemotherapy is a feared complication that may lead to progressive tissue damage. The condition may require extensive surgical intervention and often has severe long-term effects. Until a short while ago, there has been no effective treatment against the devastating effect of extravasated anthracycline. However, dexrazoxane has proven highly effective in preventing necrosis in both preclinical and clinical studies and is now approved in Europe (Savene), and has orphan drug status in the USA (Totect) for this indication. Hence, it is the first and only proven effective antidote against anthracycline extravasation injuries.

AB - Accidental extravasation of anthracycline-containing anticancer chemotherapy is a feared complication that may lead to progressive tissue damage. The condition may require extensive surgical intervention and often has severe long-term effects. Until a short while ago, there has been no effective treatment against the devastating effect of extravasated anthracycline. However, dexrazoxane has proven highly effective in preventing necrosis in both preclinical and clinical studies and is now approved in Europe (Savene), and has orphan drug status in the USA (Totect) for this indication. Hence, it is the first and only proven effective antidote against anthracycline extravasation injuries.

KW - Anthracyclines/administration & dosage

KW - Antineoplastic Agents/administration & dosage

KW - Chelating Agents/therapeutic use

KW - Clinical Trials as Topic

KW - Humans

KW - Razoxane/therapeutic use

KW - Skin Diseases/chemically induced

U2 - 10.1586/14737140.7.8.1081

DO - 10.1586/14737140.7.8.1081

M3 - Review

C2 - 18028016

VL - 7

SP - 1081

EP - 1088

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 8

ER -